证券代码：603538 证券简称：美诺华 公告编号：2026-002 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于"美诺转债"2026年付息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● "美诺转债"付息债权登记日：2026年1月13日 宁波美诺华药业股份有限公司（以下简称"公司"）于2021年1月14日公开发行的可转换公司债券将于 2026年1月14日开始支付自2025年1月14日至2026年1月13日期间的利息。根据《宁波美诺华药业股份有 限公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）有关条款规定，现将有关 事项公告如下： 10、债券期限：本期债券的期限为自发行之日起6年，即自2021年1月14日至2027年1月13日 11、上市日期：2021年2月4日 12、票面利率：本次发行的可转换公司债券票面利率为：第一年0.4%、第二年0.6%、第三年1.0%、第 四年1.5%、第五年1.8%、第六年2.0% 13、赎回条款 （1）到期赎回条款 ● ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-002 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于"美诺转债"2026 年付息的公告 1 "美诺转债"付息债权登记日：2026 年 1 月 13 日 "美诺转债"除息日：2026 年 1 月 14 日 "美诺转债"兑息日：2026 年 1 月 14 日 1、债券名称：宁波美诺华药业股份有限公司可转换公司债券 2、债券简称：美诺转债 3、债券代码：113618 4、债券类型：可转换为公司 A 股股票的可转换公司债券 5、发行总额：人民币 52,000 万元 6、发行日期：2021 年 1 月 14 日 7、发行数量：520 万张 8、票面金额：100 元/张 9、发行价格：按票面金额平价发行 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 宁波美诺华药业股份有限公司（以下简称"公司"）于 2021 年 1 月 14 日公 开发行的可转换公司债券将于 ...

Group 1 - The core viewpoint of the news is that Meinuohua has shown a positive financial performance with significant growth in revenue and net profit, alongside a stable trading activity in the stock market [2][3]. Group 2 - As of January 6, Meinuohua's stock price increased by 0.35%, with a trading volume of 111 million yuan. The financing buy-in amount was 16.10 million yuan, while the financing repayment was 14.33 million yuan, resulting in a net financing buy of 1.77 million yuan [1]. - The total financing and securities balance for Meinuohua reached 208 million yuan, accounting for 4.73% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low financing balance [1]. - On the short-selling side, there were no shares repaid or sold on January 6, with a short-selling balance of 8120 yuan, which is above the 90th percentile level over the past year, indicating a high short-selling position [1]. Group 3 - As of September 30, the number of shareholders for Meinuohua was 34,700, an increase of 7.22% from the previous period, while the average circulating shares per person decreased by 5.48% to 6229 shares [2]. - For the period from January to September 2025, Meinuohua achieved an operating income of 1.117 billion yuan, representing a year-on-year growth of 17.67%, and a net profit attributable to shareholders of 95.93 million yuan, reflecting a growth of 51.66% [2]. Group 4 - Meinuohua has distributed a total of 149 million yuan in dividends since its A-share listing, with cumulative distributions of 50.58 million yuan over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Xinhua Preferred Dividend Mixed A (519087) ranked as the seventh largest shareholder, holding 1.3129 million shares as a new shareholder [3].

Core Viewpoint - The announcement details the conversion results of the convertible bonds issued by Ningbo Meinuo Pharmaceutical Co., Ltd., highlighting the amount converted into shares and the remaining unconverted bonds as of December 31, 2025 [2][7]. Summary by Sections Convertible Bond Issuance Overview - The company issued RMB 520 million in convertible bonds on January 14, 2021, with a maturity of six years and a tiered interest rate starting from 0.4% in the first year to 2.0% in the sixth year [3]. - The bonds began trading on February 4, 2021, under the name "Meinuo Convertible Bonds" with the code "113618" [3]. - The conversion price was set at RMB 37.47 per share starting from July 20, 2021 [3]. Conversion Status - As of December 31, 2025, a total of RMB 43,609,000 of "Meinuo Convertible Bonds" has been converted into 1,178,999 shares, representing 0.788% of the total shares outstanding before conversion [2][6]. - The amount of unconverted bonds as of the same date is RMB 476,391,000, which constitutes 91.614% of the total bonds issued [7]. Recent Conversion Activity - During the period from October 1, 2025, to December 31, 2025, the conversion amount was RMB 10,000, resulting in the issuance of 386 shares, which is 0.0003% of the total shares outstanding before conversion [6].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-001 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 可转债转股结果暨股份变动公告 累计转股情况：截至 2025 年 12 月 31 日，累计共有人民币 43,609,000 元"美诺转债"已转换为公司股票，转股数量为 1,178,999 股，占可转债开始转 股前公司已发行股份总额的 0.788%。 未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的可转债金额 为人民币 476,391,000 元，占可转债发行总量的 91.614%。 本季度转股情况：自 2025 年 10 月 1 日至 2025 年 12 月 31 日期间，转股 的金额为 10,000 元，因转股形成的股份数量为 386 股。 一、可转债发行上市概况 （一） 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公 司 ...

Market Overview - The Shanghai Composite Index closed at 3968.84 points, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 2461.743 billion yuan [1] Technical Analysis - A total of 167 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sanfu New Science (三孚新科) with a difference of -1.68% [1] - Tianjian Technology (天箭科技) with a difference of -1.66% [1] - Zhongmin Energy (中闽能源) with a difference of -1.30% [1] Individual Stock Performance - Sanfu New Science (688359) decreased by 0.25% with a trading turnover of 1.57% [1] - Tianjian Technology (002977) saw a significant drop of 9.99% with a trading turnover of 2.27% [1] - Zhongmin Energy (600163) declined by 2.17% with a trading turnover of 1.33% [1] - Other notable stocks include: - Hainan Ruize (002596) increased by 0.94% [1] - Weidao Nano (688147) decreased by 1.54% [1] - Eighty Billion (688181) increased by 0.31% [1] Additional Stock Movements - Stocks such as Xiling Information (300588) and Zhaolong Interconnect (300913) also showed minor declines of 0.11% and 1.55% respectively [1] - The performance of ST stocks included: - ST Huaxi (002630) with a decrease of 0.40% [1] - ST Meicheng (300237) with a decline of 1.90% [1]

Group 1 - The core point of the announcement is the third exercise period of the stock option and restricted stock incentive plan, allowing for the exercise of 1,976,997 stock options from January 17, 2025, to December 29, 2025, with 518,448 shares exercised by the end of the period, accounting for 26.22% of the total exercisable amount [2][23][21] - The decision-making process for the stock option exercise was approved by the board of directors and the supervisory board on November 18, 2021, with independent directors providing their consent [3][6] - The company has adjusted the number of incentive participants from 327 to 302 due to voluntary withdrawals, maintaining the total stock options at 3,865,060 and restricted stocks at 1,734,940 [7][8] Group 2 - The stock options exercised will be listed for trading on the second trading day after the exercise date, with the first trading day being January 17, 2025 [23] - The total funds raised from the exercised shares amount to 11,779,138.56 yuan, with the stock options being issued as ordinary shares [26] - The company confirms that the exercise of stock options will not have a significant impact on its financial status or operational results [27] Group 3 - The company plans to use idle raised funds for cash management, amounting to 10 million yuan, to enhance the efficiency of fund utilization [31][32] - The funds for cash management will come from idle convertible bond proceeds, which totaled 520 million yuan, netting 512.7 million yuan after expenses [33] - The cash management will not affect the implementation of investment projects and is expected to improve the returns on idle funds [34][38]

| | | 宁波美诺华药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 重要内容提示： 特别风险提示：公司购买的上述理财产品为固定利率收益型的投资产品， 属于低风险投资产品，但不排除该项投资可能受到市场波动、宏观金融政策变化 等影响。 一、本次现金管理概况 （一）本次现金管理目的 为进一步提高募集资金使用效率，宁波美诺华药业股份有限公司（以下简称 "公司"）于 2025 年 12 月 30 日使用闲置募集资金进行现金管理。本次使用闲 置募集资金进行现金管理不会影响公司主营业务的发展，公司资金使用安排科学 合理。 （二）本次现金管理金额 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次使用闲置募集资金进行现金管理总金额为 1,000 万元。 1 序 号 受托方 产品名称 产品 类型 产品 期限 金额 （万元） 已履行的 审议程序 1 招商银行 招商银行单位大额存单 2025 年第 5834 期 大额 存单 - 1,000 已经公司 2025 年 4 月 17 日召开的第五届董 事会第十三次会议，以 及 2025 ...

一、本次股票期权行权的决策程序及相关信息披露 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-124 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于 2021 年股票期权与限制性股票激励计划首次授予 第三个行权期自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次行权股票数量：2021 年股票期权与限制性股票激励计划首次授予股 票期权第三个行权期可行权数量为 1,976,997 份，行权期为 2025 年 1 月 17 日至 2025 年 12 月 29 日。截至 2025 年 12 月 29 日，累计行权 518,448 股，占首次授 予股票期权第三个行权期可行权总量的 26.22%。 本次行权股票上市流通时间：公司本次行权方式为自主行权，激励对象 行权所得股票于行权日（T 日）后的第一个交易日（T+1 日）到达股票账户，并 于第二个交易日（T+2 日）上市交易。 1 ...

Group 1 - The company held its 22nd meeting of the fifth board of directors on December 24, 2025, where all five directors attended, and the meeting complied with relevant laws and regulations [2][4]. - The board approved the proposal not to adjust the conversion price of the convertible bonds, "Meinuo Convertible Bonds" [3][5]. - The decision was made despite the stock price being below the conversion price threshold, which triggered the adjustment clause [9][16]. Group 2 - As of December 24, 2025, the company's stock had closed below 90% of the current conversion price (25.68 CNY/share) for at least 15 out of the last 30 trading days, indicating a potential adjustment [9][16]. - The next period for triggering the conversion price adjustment clause will restart from December 25, 2025, and the board will decide on any future adjustments if triggered again [9][16]. - The initial conversion price of the "Meinuo Convertible Bonds" was set at 37.47 CNY/share, with subsequent adjustments made over time due to various corporate actions [10][11].